

IN THE CLAIMS

1. **(Original)** An isolated, purified or recombinant complex comprising a POSH polypeptide and a POSH-associated protein (POSH-AP).
2. **(Original)** The complex of claim 1, wherein the POSH-AP comprises a polypeptide selected from the group consisting of: PKA, SNX1, SNX3, ATP6V0C, PTPN12, PPP1CA, GOSR2, CENTB1, DDEF1, ARF1, ARF5, PACS-1, EPS8L2, HERPUD1, UNC84B, MSTP028, GOCAP, EIF3S3, SRA1, CBL-B, RALA, SIAH1, SMN1, SMN2, SYNE1, TTC3, VCY2IP1 and UBE2N (UBC13).
3. **(Cancelled)**
4. **(Currently Amended)** The complex of claim 1 ~~any one of claims 1-3~~, wherein the POSH polypeptide is a human POSH polypeptide.
- 5-6. **(Cancelled)**
7. **(Currently Amended)** A method for identifying an agent that modulates an activity of a POSH polypeptide or POSH-AP, the method comprising identifying an agent that disrupts a complex of claim 1 ~~any one of claims 1-3~~, wherein an agent that disrupts a complex claim 1 ~~of any of claims 1-3~~ is an agent that modulates an activity of the POSH polypeptide or the POSH-AP.
8. **(Currently Amended)** ~~A method of identifying an antiviral agent, The method of claim 7, further comprising:~~
 - (a) ~~identifying a test agent that disrupts a complex comprising a POSH polypeptide and a POSH-AP; and~~
 - (b) evaluating the effect of the test agent on a function of a virus,
wherein an agent that inhibits a pro-infective or pro-replicative function of a virus is an antiviral agent.
9. **(Original)** The method of claim 8, wherein the POSH-AP is selected from the group consisting of: PKA, SNX1, SNX3, PTPN12, GOSR2, CENTB1, ARF1, ARF5,

PACS-1, EPS8L2, HERPUD1, SMN1, SMN2, UNC84B, MSTP028, GOCAP, CBL-B, SYNE1, UBE2N (UBC13), SIAH1, TTC3, WASF1, HIP55, RALA, and SPG20.

10. (Original) The method of claim 8, wherein the virus is an envelope virus.
11. (Original) The method of claim 8, wherein the virus is a Human Immunodeficiency Virus.
12. (Cancelled)
13. (Cancelled)
14. (Original) The method of claim 8, wherein evaluating the effect of the test agent on a function of the virus comprises evaluating the effect of the test agent on the budding or release of the virus or a virus-like particle.
- 15-23. (Cancelled)
24. (Original) A method of identifying an agent that inhibits the progression of a neurological disorder, comprising:
 - (a) identifying a test agent that disrupts a complex comprising a POSH polypeptide and a POSH-AP; and
 - (b) evaluating the effect of the test agent on the trafficking of a protein through the secretory pathwaywherein an agent that disrupts localization of a POSH-AP is an agent that inhibits progression of a neurological disorder.
25. (Original) The method of claim 24, wherein the POSH-AP is selected from the group consisting of: HERPUD1, CBL-B, SIAH1, and TTC3.
26. (Original) The method of claim 25, wherein the POSH-AP is HERPUD1.
- 27-62. (Cancelled)

63. **(Original)** A method of identifying an agent that modulates a POSH function, comprising:

- a) identifying an agent that modulates a POSH-AP; and
- b) testing the effect of the agent on a POSH function.

64. **(Cancelled)**

65. **(Currently Amended)** The method of claim ~~63~~~~64~~ or 65, wherein the POSH-AP comprises a polypeptide selected from the group consisting of: PKA, SNX1, SNX3, ATP6V0C, PTPN12, PPP1CA, GOSR2, CENTB1, DDEF1, ARF1, ARF5, PACS-1, EPS8L2, HERPUD1, UNC84B, MSTP028, GOCAP, EIF3S3, SRA1, CBL-B, RALA, SIAH1, SMN1, SMN2, SYNE1, TTC3, VCY2IP1 and UBE2N (UBC13).

66. **(Cancelled)**

67. **(Currently Amended)** The method of claim ~~63~~~~64~~ or 65, wherein testing the effect of the agent on a POSH function comprises testing the effect of the agent on the production of viral particles or virus like particles in a cell infected with an envelope virus.

68. **(Currently Amended)** The method of claim ~~63~~~~64~~ or 65, wherein testing the effect of the agent on a POSH function comprises testing the effect of the agent on a POSH enzymatic activity.

69. **(Original)** The method of claim 68, wherein the POSH enzymatic activity is ubiquitin ligase activity.

70. **(Currently Amended)** The method of claim ~~63~~~~64~~ or 65, wherein testing the effect of the agent on a POSH function comprises testing the effect of the agent on POSH-mediated localization or secretion of a protein.

71. **(Currently Amended)** The method of claim ~~63~~~~64~~ or 65, wherein testing the effect of the agent on a POSH function comprises testing the effect of the agent on the interaction of POSH with a POSH-AP.

72. **(Cancelled)**

73. **(Cancelled)**

74. **(Currently Amended)** The method of claim ~~63~~~~64~~ or ~~65~~, wherein the test agent is selected from among: an antisense nucleic acid, an siRNA construct, a small molecule, an antibody and a polypeptide.

75-108.(Cancelled)